Buy or sell Beam Therapeutics stock pre IPO via an EquityZen fund
Beam Therapeutics Stock
Developer of genome editing technologies.
About Beam Therapeutics Stock
Over half of the genetic errors associated with disease result from a single-letter change in the billions of bases that form the genome. In other cases, certain natural genetic variations in DNA are known to protect against disease. By changing a single letter – to eliminate errors or write in protective changes – in enough cells, base editing may help us prevent, modify, and even cure a wide range of diseases affecting patients’ lives.
J. Keith Joung
Chief Scientific Officer
David R. Liu
Co-Founder and Board Member
Chief Executive Officer and Board Member
Global University Venturing - May, 15 2018
Wall Streets Journal - Mar, 6 2019